Corcept Therapeutics Incorporated (CORT)

Total asset turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 675,040 628,555 569,610 523,529 482,375 450,026 428,153 413,824 401,858 397,624 392,027 380,229 365,978 352,891 343,087 340,064 353,874 356,034 351,212 334,904
Total assets US$ in thousands 840,553 784,257 714,555 655,935 621,517 594,022 524,625 617,848 583,430 533,255 496,364 468,123 423,756 585,399 568,480 552,398 571,731 534,125 497,823 445,494
Total asset turnover 0.80 0.80 0.80 0.80 0.78 0.76 0.82 0.67 0.69 0.75 0.79 0.81 0.86 0.60 0.60 0.62 0.62 0.67 0.71 0.75

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $675,040K ÷ $840,553K
= 0.80

Corcept Therapeutics Incorporated's total asset turnover has exhibited a downward trend from March 2020 to September 2021, indicating a decrease in efficiency in generating sales from its assets during this period. However, there was a significant improvement in total asset turnover in the last quarter of 2021, reaching 0.86, which suggests the company was able to generate more revenue relative to its assets at that time.

Subsequently, total asset turnover showed some fluctuations between 0.67 and 0.82 from March 2022 to June 2023, before stabilizing around 0.80 from June 2024 to December 2024. A total asset turnover ratio of 0.80 means that for every dollar of assets Corcept Therapeutics has, it generates $0.80 in sales revenue. This indicates the company's relatively stable efficiency in utilizing its assets to generate sales during the latter part of the analyzed period. Strategically focusing on maintaining or increasing this ratio can help the company optimize its asset utilization and drive profitability.